Evidence map›Paper›PMID 25057313›Full record

ReviewTheranostics2014

Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.

Mohamed Shehata Draz, Binbin Amanda Fang, Pengfei Zhang, Zhi Hu, Shenda Gu, Kevin C Weng, Joe W Gray, Fanqing Frank Chen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 228 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Recent Update on siRNA Therapeutics.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. BioMOF-Based Anti-Cancer Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023
    Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Mohamed Shehata Draz1. Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou, Zhejiang 310029, China ; 2. Faculty of Science, Tanta University, Tanta 31527, Egypt.
Binbin Amanda Fang3. Life Sciences College, Fudan University, Shanghai 200433, China ; 4. Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94127, USA.
Pengfei Zhang5. Translational Medicine Center, Changzheng Hospital, The Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, P.R. China.
Zhi Hu6. Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, OR 97239, USA.
Shenda Gu6. Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, OR 97239, USA.
Kevin C Weng4. Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94127, USA.
Joe W Gray4. Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94127, USA ; 6. Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, OR 97239, USA.
Fanqing Frank Chen1. Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou, Zhejiang 310029, China ; 3. Life Sciences College, Fudan University, Shanghai 200433, China ; 4. Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94127, USA.
Lawrence Berkeley National Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA interference (RNAi) is an endogenous post-transcriptional gene regulatory mechanism, where non-coding, double-stranded RNA molecules interfere with the expression of certain genes in order to silence it. Since its discovery, this phenomenon has evolved as powerful technology to diagnose and treat diseases at cellular and molecular levels. With a lot of attention, short interfering RNA (siRNA) therapeutics has brought a great hope for treatment of various undruggable diseases, including genetic diseases, cancer, and resistant viral infections. However, the challenge of their systemic delivery and on how they are integrated to exhibit the desired properties and functions remains a key bottleneck for realizing its full potential. Nanoparticles are currently well known to exhibit a number of unique properties that could be strategically tailored into new advanced siRNA delivery systems. This review summarizes the various nanoparticulate systems developed so far in the literature for systemic delivery of siRNA, which include silica and silicon-based nanoparticles, metal and metal oxides nanoparticles, carbon nanotubes, graphene, dendrimers, polymers, cyclodextrins, lipids, hydrogels, and semiconductor nanocrystals. Challenges and barriers to the delivery of siRNA and the role of different nanoparticles to surmount these challenges are also included in the review.

Indexed as

NanoparticlesAnimalsDrug Delivery SystemsHumansNeoplasmsRNA, Small InterferingVirus DiseasesRNA, Small InterferingCancerDeliveryNanoparticleRNA interferenceSmall interfering RNAVirus.

Identifiers

PMID25057313
PMCPMC4107289
OpenAlexW2140217618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.